734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial
- 30 April 2006
- journal article
- abstracts
- Published by Elsevier in Journal of Hepatology
- Vol. 44, S271-271
- https://doi.org/10.1016/s0168-8278(06)80734-8